Become A Featured Company

FSD Pharma’s New CEO is a Top GW Pharma Executive

Ryan Allway

November 27th, 2018

News, Top News

Canada’s cannabis industry is projected to reach C$22.6 billion over the coming years, according to Deloitte, but the market pales in comparison to the global pharmaceutical industry—which could reach more than $1 trillion by 2020. Cannabis investors shouldn’t ignore the medical side of the business, which emerging research suggests could revolutionize several medical fields—especially in neurology.

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRK: 0K9) recently appointed Rupert Haynes as Chief Executive Officer, which is significant because he formerly held a leadership position at GW Pharmaceuticals plc (NASDAQ: GWPH)—the world leader in cannabinoid research and development. Investors may want to take a closer look at the company given these developments and the ongoing progress at its Cobourg facility in Ontario.

In this article, we will look at Rupert Haynes impressive resume and how it dovetails into the company’s existing initiatives within the healthcare side of the business.

Haynes’ Impressive Resume

Rupert Haynes is a highly accomplished healthcare executive with nearly three decades of global pharmaceutical experience. Most recently, Mr. Haynes served as the Head of Global Marketing at GW Pharmaceuticals plc (NASDAQ: GWPH) in the United Kingdom. He oversaw the strategic development of the company’s cannabinoid pipeline spanning dozens of therapeutic areas, including neurodegenerative and neuropsychological conditions.

“Mr. Haynes has an impressive track record in pipeline and product development which is directly relevant to FSD’s vision of becoming a global cannabinoid-based pharmaceutical leader,” said FSD Pharma Co-Chairman Dr. Raza Bokhari. “He blends world class specialty pharmaceutical experience with a fast-paced biotech mindset that will help accelerate FSD’s growth and global expansion strategy.”

Prior to GW Pharmaceuticals, Mr. Haynes held numerous senior leadership positions at both large pharmaceutical and bespoke biotech firms, including Sobi, UCB Pharma, Bristol-Myers Squibb, UK, and Pharmacia & Upjohn. This pedigree will be invaluable to FSD Pharma as it seeks to build out its own cannabinoid-based clinical pipeline and bring innovative new products to market over the near-term.

Positioned for Strong Growth

The appointment of Rupert Haynes comes shortly after the FSD Pharma announced its intent to acquire Therapix Biosciences to develop novel cannabinoid therapies in pain, migraine, and other central nervous system disorders. Therapix’s flagship clinical program is THX-110, a proprietary combination drug based on dronabinol and PEA, which is undergoing two Phase II studies in Tourette Syndrome and obstructive sleep apnea.

The company also partnered with SciCann Therapeutics to develop novel cannabinoid products targeting a wide range of diseases. Most recently, the company announced the start of a pilot study evaluating SciCann’s proprietary “Steady Stomach” cannabidiol (CBD) combination product for the treatment of irritable bowel syndrome patients. These kinds of partnerships could significant advance its pipeline at a relatively low cost.

In addition to these clinical programs, the company is building out a 25,000 sq. ft. indoor grow space in a former Kraft plant in Ontario, with an additional 220,000 sq. ft. pending Health Canada’s approval. Management expects the facility to become operational during the first quarter of next year, and the facility could eventually support upwards of 3.8 million sq. ft. of cultivation space—potentially making it one of the largest indoor cultivators in the country.

Looking Ahead

FSD Pharma Inc. (CSE: HUGE) (OTC: FSDDF) (FRK: 0K9) represents a compelling investment opportunity within Canada’s nascent cannabis industry. With seasoned CEO at the helm, the company is well positioned to advance its cannabinoid-based clinical portfolio in conjunction with its partners. The company is also making progress at its Cobourg facility in Ontario that could make it one of the largest indoor licensed producers.

For more information, visit the company’s website at www.fsdpharma.com.

Disclaimer 

The above article is sponsored content. Emerging Growth LLC, which owns CannabisFN.com and CFN Media, has been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.

Network Partners

Follow Us on Social Media

LinkedIn

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading